Bhargav

[SMT Global @SMTStents]

📯 We are proud that our Managing Director – Mr Bhargav Kotadia has been awarded in the @ET40underforty list of 2023
👋 Heartiest Congratulations @bkotadia
Thank you @EconomicTimes

#ET40underforty #youngleaders #innovationinhealthcare #smt #40under40 #awards2023 #leadership

[SMT Global @SMTStents]

How Indian stent maker SMT is taking the battle to MNC shores!

#Supraflex #SMT #EuroPCR #DES #cardiology #cardiacnews #clinicaltrials #MedicalDevices #stent #indianstent #MakeInIndia @moneycontrolcom @CNBCTV18News

https://t.co/wqKCG7U7xy

[KTR, Former Minister @MinisterKTR]

Bhargav Kotadia, MD, @SMTStents met Minister @KTRTRS at Camp Office today. Later in the day, SMT has announced an investment of Rs 250 crore to set up an integrated manufacturing unit of minimally invasive life-saving medical devices at the Medical Device Park, Sultanpur. 1/2

[theheartorg | Medscape @theheartorg]

TALENT all-comers trial: Ultrathin Supraflex sirolimus-eluting stent hit its primary noninferiority endpoint against the workhorse Xience everolimus-eluting stent. https://t.co/ItuaZDl7Z8 #TCT2018

[The Times Of India @timesofindia]

Made in India coronary stents as good as foreign ones: Study

https://t.co/GYeZ82v3ic

[Swadisha NGO @Swadisha]

Made in India Supraflex stent clinically at par with Abbott’s Xience, finds TALENT Study https://t.co/kY40HZEAE6

[BioVoice News @BiovoiceNews]

MED-TECH: #Supraflex, a #cardiac drug eluting stent designed & manufactured in India has been confirmed to be at par with Abbott’s #Xience through an investigators-driven study called ‘TALENT’. https://t.co/2sJ7P88k6y via @BioVoiceNews #medtech #MakeInIndia

[Poonam Velagapudi @Pooh_Velagapudi]

‘TALENT’ trial shows the Supraflex biodegradable polymer SES was non inferior to the Xience EES for DOCE at 12 months! #TCT2018 @SVRaoMD @Drroxmehran @crfheart @Kandzari

[Marion Webb @medtechMarion]

Randomized, all-comers study showed Indian-made SupraFlex SES, ultra-thin strut DES compared favorable to Abbott's Xience EES at 1-yr, said Patrick Serruys presenter TCT. What impact will this have on innovation, pricing pressures? #TCT2018

[ACC Media Center @ACCmediacenter]

ACC past President Dr. Spencer King discussed the TALENT results at #TCT2018. https://t.co/k5g7apWZt3 @ToddNeale @TCTMD

[TCTMD @TCTMD]

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers https://t.co/Cxr3XKScj1

[C. Michael Gibson MD @CMichaelGibson]

TALENT Trial: In an all-comer population, the Supraflex biodegradable polymer SES was non-inf to Xience durable polymer EES for primary endpt (CV death, tv-MI, TL-Revasc ) through 12 months.

Download the full slideset here:
https://t.co/MuUYRDdrkv

#TCT2018

[Nishaki Mehta MD @Nishaki1]

@narendramodi

[Nishaki Mehta MD @Nishaki1]

India has capped drug eluting stent price at $440 and the talent study showed that an affordable stent was non inferior paving new avenues to provide more affordable care. I️ hope some of this market competitiveness spills over for device care and NOACs! https://t.co/srDlJVBwD9

[Express Healthcare @ExpHealthcare]

Made in India #Supraflex stent clinically at par with Abbott's #Xience, finds TALENT study https://t.co/1TXx4mvNAn #health #healthcare #healthiness #HealthyLife

[SMT Global @SMTStents]

Proud Moment
#TCT2018 #TalentTrial #SupraflexCruz #Cardiology #cardiologist #SMT #Stent #MedicalDevices #India #Conference #TCT18 #TCTConference

[Bhargav @bkotadia]

The New Student Performance Measures http://t.co/RtvBMutnMK

[Bhargav @bkotadia]

@Meggyboobear, you must have him get in touch with me! I would love a mini-me :)